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Abstract
Liposomes composed of synthetic dialkyl cationic lipids and zwitterionic phospholipids such as dioleoylphosphatidyl-
ethanolamine have been studied extensively as vehicles for gene delivery, but the broader potentials of these cationic
liposomes for drug delivery have not. An understanding of phospholipid-cationic lipid interactions is essential for rational
development of this potential. We evaluated the effect of the cationic lipid DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-
trimethylammonium) on liposome physical properties such as size and membrane domain structure. DSC (differential
scanning calorimetry) showed progressive decrease and broadening of the phase transition temperature of dipalmitoylphos-
phatidylcholine (DPPC) with increasing fraction of DOTAP, in the range of 0.4^20 mol%. Laurdan (6-dodecanolyldi-
methylamino-naphthalene), a fluorescent probe of membrane domain structure, showed that DOTAP and DPPC remained
miscible at all ratios tested. DOTAP reduced the size of spontaneously-forming PC-containing liposomes, regardless of
the acyl chain length and degree of saturation. The anionic lipid DOPG (dioleoylphosphatidylglycerol) had similar effects
on DPPC membrane fluidity and size. However, DOTAP/DOPC (50/50) vesicles were taken up avidly by OVCAR-3
human ovarian tumor cells, in contrast to DOPG/DOPC (50/50) liposomes. Overall, DOTAP exerts potent effects on
bilayer physical properties, and may provide advantages for drug delivery. ß 2001 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Liposomes composed of cationic lipids and helper
phospholipids have been shown to be e¡ective ve-
hicles for cellular delivery of RNA and DNA [1^4].
For example, liposomes containing the cationic lipids
DOTMA (N-[1-(2,3-dioleyloxy)propyl]-N,N,N-tri-
methylammonium) or DOTAP (N-[1-(2,3-diole-
oyloxy)propyl]-N,N,N-trimethylammonium) (Fig. 1),
form strong complexes with DNA, and the addition
of positive charge to the liposome surface enhances
the interaction with cellular membrane components
[1,5^7].
There exists a wide range of situations in which the
ability to provide overall cationic electrostatic charge
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to liposomes could be advantageous [8]. For exam-
ple, the addition of charge can inhibit aggregation of
liposomes, but in some cases, such as the encapsula-
tion of polycationic drugs or peptides, anionic lipids
would be unsuitable. Stearylamine (octadecylamine),
a monoalkyl cationic lipid, has been used widely to
provide cationic charge to liposomes [9^12]. How-
ever, rapid extraction or exchange of stearylamine
from the bilayer in the presence of cells or plasma
proteins, as well as potential toxic e¡ects, represent
limitations [8,13^15]. Dialkyl or diacyl lipids such as
DOTAP and DOTMA should be more stable in the
membrane bilayer, based on the enthalpic and en-
tropic contributions resulting from the incorporation
of additional hydrocarbon chains in the membrane
bilayer. These or similar lipids have been used both
in vitro and in vivo, and have shown minimal tox-
icity in a number of applications [16^19].
Cationic liposomes designed for nucleic acid deliv-
ery generally are intrinsically unstable and undergo a
structural transition upon interacting with the poly-
anionic nucleic acids or serum components [3,5,20^
22]. Membrane conformational instability, which ap-
pears essential to the delivery function, is enhanced
by inclusion of a helper lipid; the most common is
phosphatidylethanolamine (PE). PE is a zwitterionic
phospholipid that is unable to form stable bilayer
vesicles at neutral pH in physiological saline, and it
readily undergoes a bilayer to hexagonal phase tran-
sition [23,24]. In contrast, liposomes used for drug or
peptide delivery should be intrinsically stable in or-
der to retain their contents. Such stability might be
achieved nominally by the substitution of phosphati-
dylcholine (PC), a zwitterionic phospholipid that
forms stable bilayers, for PE, and by the inclusion
of high phase transition lipids that inhibit interaction
with serum proteins and promote the retention of
liposome contents [25].
In the present work, we have studied the interac-
tions of cationic lipids with phospholipids that form
stable bilayer vesicles, and have examined their ef-
fects on liposome physical properties. DSC (di¡er-
ential scanning calorimetry) was used to evaluate
the physical e¡ect of DOTAP on thermotropic phase
behavior. Fluorescence spectroscopy using Laurdan
(6-dodecanolyldimethylamino-naphthalene) and
DPH (1,6-diphenyl-1,3,5-hexatriene) was employed
to probe the membrane interfacial region and do-
main structure, as well as the acyl chain region of
membrane vesicles. QLS (quasi-elastic light scatter-
ing) was used to evaluate the e¡ect of cationic lipids
on the size of spontaneously-forming vesicles. Fi-
nally, £uorescence microscopy was used to provide
an overview of cellular interactions of PC-containing
cationic liposomes.
2. Materials and methods
2.1. Materials
Dimyristoylphosphatidylcholine (DMPC), dipal-
mitoylphosphatidylcholine (DPPC), distearoylphos-
phatidylcholine (DSPC), dioleoylphosphatidylcholine
(DOPC), dioleoylphosphatidylglycerol (DOPG),
phosphatidylglycerol (PG) from egg yolk and the
cationic lipid DOTAP were obtained from Avanti
Polar Lipids (Alabaster, AL, USA). All lipids were
stored at 380‡C in chloroform under an inert atmos-
phere. HPLC grade solvents (water and ethanol)
were obtained from Fisher Scienti¢c. Laurdan (6-do-
decanolyldimethylamino-naphthalene), DPH (diphe-
nylhexatriene), and rhodamine-dipalmitoylphospha-
tidylethanolamine were obtained from Molecular
Probes (Eugene, OR, USA). Cell culture media and
serum were obtained from Gibco-BRL (Gaithers-
burg, MD, USA).
Fig. 1. Chemical structure of cationic lipids.
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2.2. Preparation of liposomes
The required amount of lipid was dissolved in
chloroform at 20 mM, and the solvent was removed
using a rotary evaporator to form a thin ¢lm on the
walls of a screw-cap tube. The ¢lm was then hy-
drated with water in an inert atmosphere, incubated
above the bilayer phase transition temperature of the
phospholipid employed, and vortexed intermittently.
The speci¢c concentration of lipid used for each
study was determined by the experimental require-
ments, and was typically 10^20 mM.
2.3. Di¡erential scanning calorimetry
Thermograms were obtained using a Perkin Elmer
DSC-2 calorimeter with samples sealed in aluminum
pans. The instrument was calibrated with an indium
standard. The thermograms were recorded using a
heating rate of 2.5 K/min and a range of 1 mCal/s.
For each scan, 13 Wl of a liposome suspension of
approximately 80 mM phospholipid was used. Sam-
ples previously equilibrated above their phase tran-
sition were held at an initial temperature of 25‡C for
at least 15 min before obtaining each thermogram.
To generate a phase diagram, triplicate samples were
prepared for each phospholipid/DOTAP ratio and
immediately analyzed. For each sample, the peak
height and width, and the transition temperature
were measured.
2.4. Membrane lamellar domains
Excitation and emission spectra of Laurdan (6-do-
decanolyldimethylamino-naphthalene) were obtained
using an SLM Aminco 8000 series instrument. Laur-
dan, which is fully miscible in gel and liquid crystal-
line phases of membranes, was used to characterize
the e¡ects of DOTAP on the phase domain proper-
ties [26^28] of DPPC vesicles over the temperature
range 30^70‡C. Laurdan was incorporated in lipo-
somes at a ratio of 1/3000 (Laurdan/lipid). The total
concentration of lipid used for each measurement
was 0.5 mM. The excitation spectra were acquired
over the range 320^400 nm, and the emission wave-
lengths were set sequentially at 440 nm and 490 nm.
The temperature was equilibrated for at least 15 min
before acquiring spectra.
2.5. Generalized polarization
Laurdan excitation spectra were obtained as de-
scribed above, using ¢xed emission wavelengths of
440 and 490 nm. Generalized polarization (GP) val-
ues at each point in the excitation spectrum were
calculated according to the following formula:
GP  I4403I490=I440  I490
[26^28], where ‘I’ represents the £uorescence intensity
for each discrete excitation wavelength as detected at
440 and 490 nm.
2.6. Fluorescence polarization and £uidity
Measurements were made using an excitation
wavelength of 355 nm, an emission wavelength of
430 nm, 4 nm excitation and emission slits, and
FP110 ¢lm polarizers. To incorporate DPH into
small unilamellar vesicles, a stock solution of 2 mM
DPH was prepared in tetrahydrofuran, and 2 Wl
was added to 2 ml of cationic liposomes (0.6 mM
phospholipid). The sample was mixed vigorously
above the phase transition of the phospholipid em-
ployed. The cuvette chamber was maintained at the
required temperature using a circulating water bath,
and was allowed to equilibrate for 15^20 min prior
to £uorescence measurements. Fluorescence polariza-
tion (P) was calculated by the following formu-
la:
P  I0; 03GUI0; 90=I0; 0  GUI0; 90;
G  I90; 0=I90; 90
[29], where ‘I’ represents the £uorescence intensity
using an excitation wavelength of 355 nm and an
emission wavelength of 430 nm.
2.7. Quasi-electric light scattering
A particle sizer (Nicomp Particle Sizing Systems
model 370, Santa Barbara, CA, USA), was used to
investigate the e¡ect of DOTAP on liposome size.
All liposome formulations were made in triplicate
and analyzed without sonication or extrusion. The
measurements were carried out at 25‡C, with an ac-
quisition time of approximately 2 min and a lipid
concentration of 2.9 mM. The volume-weighted
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NICOMP analysis was applied to estimate size dis-
tribution.
2.8. Fluorescence microscopy
Liposomes labeled with rhodamine-DPPE (N-
(Lissamine rhodamine B sulfonyl)-dipalmitoylphos-
phatidylethanolamine) were used to investigate the
e¡ect of charge on uptake of liposomes by human
ovarian tumor cells. The cell line OVCAR-3, ob-
tained as described previously [30], was plated on
sterile cover slips in 6-well plates (Costar, Cam-
bridge, MA, USA) at a density of 5U105 cells per
ml of media. The cells were allowed to adhere over-
night in RPMI 1640 media containing 10% fetal bo-
vine serum, and were treated with 100 nmol of rhod-
amine labeled liposomes on the following day. The
liposome formulations consisted of DOPC/DOTAP
(50/50) or DOPG/DOTAP (50/50), and included
1 mol% rhodamine-DPPE. After 1 h at 37‡C, the
cells were washed with cold phosphate-bu¡ered
saline (to remove free liposomes and any cellular
debris), and the cells were analyzed by £uorescence
microscopy (40U objective lens).
3. Results
3.1. The e¡ect of DOTAP on the phase transition of
DPPC
Di¡erential scanning calorimetry (DSC) was car-
ried out to investigate the e¡ect of DOTAP on mem-
brane physical properties. Fig. 2 shows the e¡ect of
DOTAP mol fraction on the thermal phase transition
of large DPPC vesicles. Liposomes composed of
DPPC alone showed a highly cooperative acyl chain
melting transition at 41.3‡C (314.3 K; data not
shown) [31]. At lower DOTAP concentrations
(90.2%), the e¡ect of DOTAP on the thermal phase
transition of DPPC was minimal. As the concentra-
tion of DOTAP increased (0.4 to 2.5 mol%), a shift
in the thermal phase transition toward lower temper-
atures was observed (Fig. 2). Such a shift may sug-
gest packing defects at the membrane interface. As
the mol fraction of DOTAP increased, broadening of
the DPPC peak was observed, and the DPPC phase
transition was abolished v25 mol% DOTAP (Fig. 2).
The DSC thermograms were used to construct a
phase diagram in order to characterize the e¡ects of
DOTAP on the thermal phase behavior of DPPC
(Fig. 2). For pure DPPC, a single-component system,
two phases (gel and liquid crystalline) coexist over a
narrow range of temperatures. As the concentration
of DOTAP increased (910 mol%), there was an ob-
servable increase in the temperature range over
which the gel and liquid crystalline phases coexist.
Above 20 mol% of DOTAP, the coexisting phase
was completely abolished, and the DOTAP/DPPC
mixtures formed an apparently homogeneous liquid
crystalline phase. Because of extensive peak broad-
ening, it was not possible to use DSC to investigate
bilayer state at DOTAP ratios above 20 mol%.
3.2. Laurdan £uorescence: properties of lamellar
domains
The state of the bilayer above 20 mol% DOTAP is
of potential interest for drug delivery [1,2]; high
charge densities may be required for optimal cell
Fig. 2. E¡ect of DOTAP on thermal phase transition of DPPC
vesicles. Multilamellar liposomes containing varying concentra-
tions of DOTAP (0^20 mol%) were prepared as described in
Section 2. The DPPC concentration was 80 mM for all sam-
ples. Samples were prepared in triplicate and analyzed by DSC
immediately. The phase transition temperature was determined
graphically from analog scans, and is plotted as a function of
the mol% DOTAP in DPPC. Vertical bars at each point repre-
sent the peak width at half-height. Dotted lines connecting the
maxima and minima of the vertical bars indicate approximate
phase boundaries. Boundaries drawn beyond the data (s 20
mol%) are estimated from Laurdan £uorescence data, as de-
scribed in the text.
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Fig. 3. Temperature-dependent excitation spectra of Laurdan in DPPC and DPPC/DOTAP liposomes. Laurdan was incorporated into
multilamellar liposomes of (A) DPPC (100%), and (B) DPPC/DOTAP (50/50 mol%). Excitation spectra were acquired at various tem-
peratures spanning the phase transition temperature of DPPC, using an emission wavelength of 440 nm. The symbols and tempera-
tures to which they are assigned are shown in the inset for each panel.
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Fig. 4. General polarization as a function of wavelength for DPPC and DPPC/DOTAP liposomes. Excitation spectra of Laurdan-con-
taining multilamellar liposomes composed of (A) DPPC (100%), and (B) DPPC/DOTAP (50/50) were acquired at various temperatures
spanning the phase transition temperature of DPPC, using emission wavelengths of 440 nm and 490 nm. General polarization was cal-
culated at each excitation wavelength as described in Section 2. The symbols and temperatures to which they are assigned are shown
in the inset for each panel.
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interaction or incorporation of substances for encap-
sulation. Fluorescence spectroscopy was used to
probe the compositions of DPPC/DOTAP not ame-
nable to study by DSC, and to test the speci¢c hy-
potheses that DOTAP perturbs the membrane water/
hydrocarbon interfacial region or alters lipid misci-
bility.
The excitation spectrum of Laurdan is sensitive to
lamellar phase properties, and does not partition se-
lectively in di¡erent lipid domains [26]. The excita-
tion spectrum has two peaks: one at 350 nm and the
other at 390 nm. The relative intensity of these peaks
is sensitive to the phase state of the membrane; in
the gel state (T9 41.3‡C), the intensity at 350 nm is
greater than that at 390 nm, whereas in the liquid
crystalline phase (Tv 41.3‡C), the 390 nm band is
slightly more intense than the band at 350 nm.
Laurdan spectra were acquired for DPPC/DOTAP
vesicles at temperatures spanning the bilayer phase
transition of DPPC (Fig. 3A). From the relative
heights of the 350 and 390 nm excitation peaks, the
data suggest that the bilayer exists in the gel phase
over the temperature range 30^40‡C. As the temper-
ature increased above 40‡C, an abrupt decrease was
observed in £uorescence intensity at 390 nm, indicat-
ing transition from the gel to the liquid crystalline
phase.
Fig. 3B shows Laurdan excitation spectra for
DPPC/DOTAP (50/50) liposomes. At the lowest tem-
peratures (30‡C), the membrane existed almost en-
tirely in the liquid crystalline phase, based on the
intensity of the 350 and 390 nm peaks. Therefore,
DOTAP induced an earlier onset of the liquid crys-
talline phase in DPPC membranes. This observation
is consistent with the DSC studies that showed DO-
TAP to lower the phase transition temperature of
DPPC membranes containing 9 20 mol% DOTAP.
3.3. General polarization of the bilayer phases
Laurdan can provide additional information on
the state of the bilayer phase, such as the relative
fractions of gel and liquid crystalline domains when
those phases coexist. Therefore, the generalized po-
larization (GP) of Laurdan was calculated from £uo-
rescence spectral scans. GP values of approximately
0.6 and 30.2 correspond to the gel and liquid crys-
talline phases, respectively [26^28]. In addition, the
wavelength dependence of GP is smaller for gel state
lipid than for lipid in the liquid crystalline phase
state; this phenomenon arises from the high rate of
solvent relaxation in the liquid crystalline membrane
at higher temperatures, which leads to excited state
stabilization and a red shift in the £uorescence emis-
sion [26^28].
The steady-state GP value was calculated for each
excitation wavelength [26], as described in Section 2,
and data were acquired to determine GP as a func-
tion of temperature and liposome composition. From
the excitation spectra of 100% DPPC (Fig. 4A), the
gel phase at 30‡C has a GP value of 0.4, and the GP
was independent of excitation wavelength. The exci-
tation spectra at 41‡C, a temperature at which gel
and liquid phase coexist, gave a GP value of 0.0,
and the GP was slightly more dependent on wave-
length than it was in the gel phase. A stronger de-
pendence of GP on wavelength was observed for the
liquid crystalline phase at 70‡C (GP =30.4).
At most temperatures, the GP values of DPPC
liposomes containing 50% DOTAP suggest a de-
crease in the relative amount of gel phase compared
to compositions lacking DOTAP (Fig. 4B). At 30‡C,
the GP values of DPPC/DOTAP resembled those of
DPPC at 41‡C. The GP values of DPPC/DOTAP at
v 34‡C, having a magnitude of 9 0.0, suggest the
existence of liquid crystalline phase. Overall, the
data are consistent with broadening and early onset
of the liquid crystalline phase transition in the pres-
ence of 50 mol% DOTAP.
Fig. 5 shows the e¡ect of DOTAP on the lamellar
domain structure of DPPC as a function of temper-
ature. In general, the excitation GP380nm of DPPC
and DPPC/DOTAP liposomes decreased as a func-
tion of increasing temperature, with the lowest GP
values reported at 70‡C and a sharp decrease in
GP380nm observed at approximately 41‡C, the tem-
perature at which DPPC undergoes the gel to liquid
crystalline transition.
3.4. DOTAP e¡ects on the hydrocarbon chain region
of DPPC membranes
Laurdan suggested signi¢cant perturbation of the
interfacial region of DPPC membranes by DOTAP.
The £uorescent probe DPH (diphenylhexatriene) is
located deeper within the bilayer core, and is sensi-
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tive to membrane £uidity because the probe has
greater rotational freedom in the liquid crystalline
phase [32,33]. In liposomes of DPPC alone, DPH
had a polarization value of approximately 0.45 at
25‡C (Fig. 6). 10 mol% DOTAP in DPPC, which
caused signi¢cant lowering and broadening of the
DPPC phase transition as detected by DSC (data
not shown), had no signi¢cant e¡ect on DPH mobil-
ity (data not shown). In contrast, 50 mol% DOTAP
exerted a signi¢cant e¡ect on acyl chain mobility of
DPPC-containing liposomes (Fig. 6).
To investigate whether the observed £uidizing ef-
fect arises from a unique property of the dialkyl cat-
ionic lipid, or whether the e¡ect is conferred by the
incorporation of unsaturated hydrocarbon chains
into the bilayer, a variety of other charged and un-
saturated phospholipids were substituted for DO-
TAP in DPPC membranes. Anionic and zwitterionic
phospholipids of the same hydrocarbon chain length
and saturation exerted an e¡ect similar to that of
DOTAP; 50 mol% DOPG (dioleoylphosphatidylgly-
cerol; Fig. 6) or DOPC (dioleoylphosphatidylcho-
line; data not shown) in DPPC altered acyl chain
mobility to the same extent as did 50% DOTAP.
Naturally-occurring phospholipids having a blend
of di¡erent acyl chain lengths and saturation had
an intermediate e¡ect compared to dioleoyl lipids
(Fig. 6).
The e¡ect of 50 mol% DOTAP on acyl chain mo-
bility was not restricted to DPPC; similar e¡ects
were observed for DOTAP in dimyristoylphosphati-
dylcholine (DMPC) and distearoylphosphatidylcho-
line (DSPC) liposomes (data not shown).
3.5. E¡ect of DOTAP on liposome size
Liposome diameter and size dispersity are impor-
tant parameters in drug delivery applications. QLS
(quasi-elastic light scattering) was used to determine
the e¡ect of DOTAP on the size distribution of spon-
taneously-forming liposomes as a function of phos-
pholipid acyl chain length (14:0, 16:0, 18:0), degree
of unsaturation (18:1), and concentration of DOTAP
(0^100 mol%). DOTAP reduced the mean diameter
of PC-containing multilamellar liposomes, regardless
of the phospholipid chain length and degree of un-
saturation (Fig. 7). The greatest e¡ect was observed
in the range 0^20 mol% cationic lipid; for some com-
positions the e¡ect was quite large. For example,
DSPC liposomes had a mean diameter of 3 Wm
(Fig. 7); inclusion of 20 mol% DOTAP reduced lipo-
some diameter nearly 5-fold, to 600 nm.
With increasing mol% DOTAP, both the diameter
Fig. 6. Acyl chain mobility of DPPC liposome containing DO-
TAP. Liposomes of DPPC were prepared containing 50 mol%
DOTAP, DOPG, or PG from egg yolk. DPH was added in
trace quantity and £uorescence polarization was measured as
described in Section 2. The temperature was 25‡C for each ex-
periment. The liposomes and symbols to which they are as-
signed are in the inset for each panel. Each point represents the
mean of three separate determinations, and the vertical bars on
each point indicate the standard deviation.
Fig. 5. GP as a function of temperature for DPPC and DPPC/
DOTAP liposomes. GP values for Laurdan plotted in the pres-
ence and absence of DOTAP (see Section 2), and the GP values
for 380 nm are plotted as a function of temperature for each
liposome formulation.
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and the dispersity of the vesicle population were re-
duced (data not shown); regardless of the PC used,
binary mixtures containing 50 mol% DOTAP had a
mean diameter of 0.5^1 Wm (Fig. 7). Liposomes of
100% DOTAP had a mean diameter of approxi-
mately 0.6 Wm.
To investigate whether the reduction in vesicle size
arises primarily from the inclusion of a lipid with
unsaturated alkyl chains, DOPC was substituted
for DOTAP in DPPC liposomes. Over a range of
10^100% DOPC, liposome diameter was highly var-
iable, and tended to larger mean diameters than the
equivalent DOTAP-containing DPPC formulation
(Fig. 7). Anionic unsaturated lipids also were inves-
tigated; DOPG or egg PG at 50 mol% reduced the
diameter of DPPC vesicles to sizes equivalent to DO-
TAP-containing liposomes (data not shown).
3.6. Cellular interaction
DOTAP-containing liposomes, like anionic lipo-
somes, have been shown to interact with many di¡er-
ent cell types. However, most compositions tested
previously contain large amounts of phosphatidyl-
ethanolamine, are highly unstable in the presence
of cells, and carry complexed polyanions such as
DNA which may modify their electrostatic charge.
Furthermore, cells vary in their ability to bind or
internalize liposomes [6,7,34^36]. We investigated
the extent to which liposomes of PC and high con-
centrations of DOTAP can interact with cells, and
Fig. 7. E¡ect of DOTAP on the size distribution of multilamel-
lar vesicles. Liposomes were prepared with varying ratios of
DOTAP in DMPC, DPPC, DOPC, and DSPC, or with DOPC
in DPPC. QLS was used to determine liposome diameter; sam-
ples were prepared in triplicate and analyzed at 25‡C using a
2 min acquisition time. The volume-weighted NICOMP analysis
was applied to estimate the size distribution. Liposome diameter
is shown as a function of phospholipid acyl chain length (14:0,
16:0, and 18:0), degree of unsaturation (18:1), and percent DO-
TAP (0^100 mol%). The liposomes and symbols to which they
are assigned are in the inset of the panel.
Fig. 8. Uptake of rhodamine-DPPE labeled anionic liposomes
by OVCAR-3 cells in vitro. Cells in culture were incubated for
1 h at 37‡C with 100 nmol of liposomes containing 1 mol% of
the £uorescent phospholipid rhodamine-DPPE. Cells were incu-
bated with 100 nmol of DOPC/DOPG (50/50) liposomes, and
then washed free of unbound liposomes. Phase contrast (A)
and £uorescence images (B) were acquired by microscopy
(bar = 20 Wm).
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focused on OVCAR-3, an epithelioid human ovarian
cancer cell line that has been shown to bind anionic
liposomes so poorly that it interferes with drug deliv-
ery [30,34]. As a control, anionic liposomes were pre-
pared in which DOTAP was substituted with an
equivalent mol fraction of DOPG.
When OVCAR-3 cells were exposed to 100 nmol/
ml DOPC/DOPG (50/50) for 1 h at 37‡C, few rhod-
amine-DPPE labeled liposomes were associated with
cells (Fig. 8). In contrast, DOPC/DOTAP (50/50)
liposomes showed greater cell association (Fig. 9),
and the perinuclear localization of £uorescence in
many cells suggested internalization (Fig. 10).
4. Discussion
DOTAP-containing liposomes have been studied
most extensively for DNA delivery. Such liposomes
are designed to deliver well hydrated macromolecules
across cell membranes, and the role of the ‘helper’
phospholipid, in most cases a phosphatidylethanol-
amine, has been shown to be critical for delivery
[1,2,37]. The intrinsic instability of PE-rich lipo-
somes, as well as the speci¢c non-bilayer structural
transitions which PE undergoes [5,38], appear to be
important factors in cellular delivery of nucleic acids.
In contrast, most drug delivery applications for
liposomes require properties other than intrinsic in-
stability; these include incorporation (encapsulation)
e⁄ciency, structural stability in biological media,
and, for optimal circulation time in the blood, high
phase transition lipids and small diameter. As DNA
transfection helper lipids, the phosphatidylcholines
are less e⁄cient than phosphatidylethanolamines be-
cause of their lower propensity to undergo the struc-
tural transitions important for DNA delivery. How-
ever, by reason of their greater stability, PC-
containing liposomes are more suitable for entrap-
ping and delivering therapeutic agents. Formation
Fig. 9. Uptake of rhodamine-DPPE labeled cationic liposomes
by OVCAR-3 cells in vitro. Cells in culture were incubated for
1 h at 37‡C with 100 nmol of liposomes containing 1 mol% of
the £uorescent phospholipid rhodamine-DPPE. Cells were incu-
bated with 100 nmol of DOPC/DOTAP (50/50) liposomes, and
then washed free of unbound liposomes. Phase contrast (A)
and £uorescence images (B) were acquired by microscopy.
Fig. 10. Uptake of rhodamine-DPPE labeled cationic liposomes
by OVCAR-3 cells in vitro. Phase contrast (A) and £uorescence
image (B) demonstrating £uorescence in the perinuclear region
of OVCAR-3 tumor cell 1 h after incubation with 100 nmol of
DOPC/DOTAP (50/50) liposomes, and then washed free of un-
bound liposomes before analysis (bar = 20 Wm).
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and stability of such drug/lipid formulations may be
impacted greatly by the fundamental physical char-
acteristics of the membrane, including phase transi-
tion temperature and miscibility of the cationic lipids
in the presence of zwitterionic phospholipids. There-
fore, we investigated the e¡ects of DOTAP on the
fundamental physical properties of liposomes.
DSC and Laurdan £uorescence spectroscopy were
used to investigate the e¡ect of cationic lipids on
phase behavior and membrane £uidity; both re-
ported a shift in the DPPC phase transition temper-
ature toward lower temperatures, with DSC showing
peak broadening at higher concentrations (s 10
mol%) of DOTAP. DSC was not able to detect the
physical events that occur above 20% DOTAP, ow-
ing to extensive peak broadening by DOTAP. How-
ever, £uorescence spectroscopy employing the probe
Laurdan provided information on bilayer state at
higher DOTAP concentrations. At 50% DOTAP,
the DPPC bilayer existed predominately in a homo-
geneous liquid crystalline phase, and retained its
structural integrity at elevated temperatures.
DPH polarization studies suggest DOTAP to have
charge-, chain length-, and saturation-dependent ef-
fects on membrane £uidity. Phospholipid vesicles
composed of unsaturated acyl chains with charged
head groups (e.g. DOTAP and DOPG) £uidized
membranes to a greater extent than did uncharged
unsaturated (e.g. DOPC) or charged unsaturated lip-
ids obtained from a more heterogeneous source (e.g.
egg PG).
Liposome diameter or hydrodynamic radius bears
a direct relationship to liposome clearance rates in
blood, and can exert marked e¡ects on the antitumor
activity of therapeutic agents [39,40]. For some clin-
ical applications, it may be desirable to prepare lipo-
somes immediately prior to administration by the
hydration of dry lipid powders [41^44]. Both the di-
ameter and population dispersity of such spontane-
ously-forming liposomes are critical in this applica-
tion.
The inclusion of DOTAP at v10 mol% both de-
creased the diameter of spontaneously-forming lipo-
somes and decreased particle heterogeneity. Substitu-
tion of lipids matching either charge or acyl chain
con¢guration indicated that the e¡ect on size distri-
bution did not appear to be chain length- or concen-
tration-dependent at higher mole fractions of DO-
TAP. At lower mol fractions, DOTAP exerted the
most marked e¡ect on vesicle diameter.
Because 10% DOTAP exerted potent e¡ect on
vesicle size and peak broadening (observed by
DSC), we investigated the role of membrane £uidity
in reduction of vesicle size. The unsaturated zwitter-
ionic lipid DOPC, which had a signi¢cant e¡ect on
membrane £uidity, did not reduce the size of lipo-
somes composed predominantly of DPPC; rather
DOPC inclusion resulted in a broadly variable size
distribution of liposomes. In contrast, anionic
charged unsaturated lipids not only conferred a sig-
ni¢cant increase in membrane £uidity, but also re-
duced DPPC vesicle size to a greater extent than
uncharged unsaturated lipids (data not shown).
The molecular or physical interactions working in
conjunction with membrane £uidity to reduce vesicle
size is an important question. Alterations at the
membrane interface induced by DOTAP could func-
tion in part to facilitate head group electrostatic in-
teractions. These physical interactions could promote
size reduction by decreasing the bilayer radius of
curvature as a result of phospholipid-cationic head
group contact. Molecular modeling studies con-
ducted elsewhere [45], have reported DOTAP and
DOPC head groups to be located at a similar plane
of the bilayer. It was also suggested that the quater-
nary amine of DOTAP and the phosphate group of
the phospholipid DOPC may form a salt bridge [45].
Such molecular interactions may explain, in part, the
potent e¡ect of DOTAP on vesicle size and bilayer
phase state. These physical interactions may be ex-
ploited to improve the stability and encapsulation
e⁄ciency of liposomes containing drugs [46].
Stable cationic liposomes o¡er the potential for
remarkable advancement of drug delivery applica-
tions. For example, although many cell lines bind
anionic liposomes avidly, certain human ovarian can-
cer lines appear quite resistant to liposome-mediated
delivery [30,34]. Inclusion of DOTAP results in a
drastic increase in the binding of liposomes by OV-
CAR-3 human ovarian tumor cells ; uptake of
anionic liposomes of equivalent but opposite charge,
was negligible. At relatively high concentrations of
cationic liposomes (e.g. 400 nmol/106 cells) and per-
cent charge (v50%), we observed no cytotoxicity
(data not shown). Avid uptake of cationic liposomes
by HeLa cells in culture [6], and angiogenic endothe-
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lial cells in tumors [7], have been reported, and sug-
gest applications in cell-speci¢c targeting. Based on
the e¡ect of cationic lipids on the physical stability of
liposomes [47], as well their apparent organ- and
vasculature-speci¢c uptake [4], stable cationic lipo-
somes may have a wide range of applications in
drug delivery, and represent an advance over previ-
ously described liposome formulations.
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